LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bioneer’s Combination Tests for SARS-CoV-2 and Influenza Receive CE-IVD Marking

By LabMedica International staff writers
Posted on 19 Nov 2020
Print article
AccuPower RV1 Real-Time RT-PCR Kit (Photo courtesy of Bioneer)
AccuPower RV1 Real-Time RT-PCR Kit (Photo courtesy of Bioneer)
Bioneer (Daejeon, Korea) has received CE-IVD marking for two combination tests for SARS-CoV-2 and influenza - the AccuPower RV1 Real-Time RT-PCR Kit and AccuPower RV1 Multiplex Kit.

The AccuPower RV1 Real-Time RT-PCR Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The 5-in-1 multiplex kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube. The user-convenient premix type kit enables pipetting free diagnosis since all the components for the assay are contained within a tube. It uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity, and the vacuum-dried premix allows for stable and reproducible results. The test kit is compatible with the ExiStation and ExiStation 48 systems.

The AccuPower RV1 Multiplex Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube and uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity. The test kit is compatible with various systems, including Exicycler 96 (BIONEER), CFX 96 (Bio-rad), ABI7500 Fast (Thermofisher), and Quantstudio 5 (Thermofisher).



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more